AtriCure Inc. (NASDAQ:ATRC) SVP Justin J. Noznesky sold 10,000 shares of the stock in a transaction on Monday, June 17th. The shares were sold at an average price of $30.00, for a total value of $300,000.00. Following the completion of the sale, the senior vice president now owns 94,068 shares of the company’s stock, valued at $2,822,040. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
NASDAQ ATRC traded down $0.76 during trading hours on Friday, hitting $31.38. The company’s stock had a trading volume of 151,864 shares, compared to its average volume of 220,718. AtriCure Inc. has a 52 week low of $26.11 and a 52 week high of $36.49. The stock has a market capitalization of $1.23 billion, a P/E ratio of -33.38 and a beta of 0.27. The company has a debt-to-equity ratio of 0.19, a current ratio of 4.37 and a quick ratio of 3.69. The company’s 50-day moving average price is $30.11.
AtriCure (NASDAQ:ATRC) last announced its quarterly earnings results on Thursday, April 25th. The medical device company reported ($0.20) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.24) by $0.04. The business had revenue of $53.97 million for the quarter, compared to analysts’ expectations of $52.45 million. AtriCure had a negative net margin of 7.98% and a negative return on equity of 14.35%. The firm’s revenue for the quarter was up 14.9% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.31) EPS. On average, research analysts anticipate that AtriCure Inc. will post -0.74 EPS for the current fiscal year.
A number of large investors have recently bought and sold shares of the business. Macquarie Group Ltd. increased its stake in AtriCure by 1.0% in the 4th quarter. Macquarie Group Ltd. now owns 65,786 shares of the medical device company’s stock valued at $2,013,000 after buying an additional 681 shares during the last quarter. Quantum Capital Management increased its stake in shares of AtriCure by 0.7% during the 1st quarter. Quantum Capital Management now owns 127,035 shares of the medical device company’s stock worth $3,403,000 after purchasing an additional 845 shares during the last quarter. Bell Rock Capital LLC purchased a new stake in shares of AtriCure during the 1st quarter worth approximately $26,000. Rhumbline Advisers increased its stake in shares of AtriCure by 3.4% during the 1st quarter. Rhumbline Advisers now owns 48,738 shares of the medical device company’s stock worth $1,306,000 after purchasing an additional 1,594 shares during the last quarter. Finally, Legal & General Group Plc increased its stake in shares of AtriCure by 31.0% during the 4th quarter. Legal & General Group Plc now owns 6,958 shares of the medical device company’s stock worth $213,000 after purchasing an additional 1,646 shares during the last quarter. Hedge funds and other institutional investors own 89.28% of the company’s stock.
A number of analysts have commented on ATRC shares. JPMorgan Chase & Co. set a €78.00 ($90.70) price target on shares of Porsche Automobil and gave the company a “neutral” rating in a research report on Friday, April 12th. BTIG Research started coverage on shares of GrubHub in a research report on Tuesday, April 2nd. They set a “buy” rating and a $95.00 price target on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $120.00 price target (up previously from $115.00) on shares of Synopsys in a research report on Thursday, March 28th. BidaskClub raised shares of Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, July 4th. Finally, Zacks Investment Research cut shares of Hancock Jaffe Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, June 26th. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $36.67.
AtriCure, Inc develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; EPi-Sense guided coagulation system used for the coagulation of tissue; and COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy.
Further Reading: What is the Beige Book?
Receive News & Ratings for AtriCure Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for AtriCure and related companies with MarketBeat.com’s FREE daily email newsletter.